Islam Saqib

CEO Islam Saqib sold 49,000 shares (4.9% of holdings) for $2.7M across 5 transactions on 2025-03-03

Islam Saqib, Chief Executive Officer of SpringWorks Therapeutics, executed 5 separate sales totaling 49,000 shares for $2,657,655.82 on 2025-03-03, reducing his holdings from 1,003,869 to 954,869 shares. The blended average sale price was $54.24, which is notably above the current price of $50.59 (the stock has declined 15.6% from its 52-week high of $59.93). Across his cross-ticker open-market history, Saqib's 13 prior sells have achieved a 22.22% well-timed rate (where negative 90-day returns indicate the insider sold before declines), yet his average 90-day return after sells was +10.2%, meaning those transactions were generally poorly timed as the stock rose afterward. At SWTX specifically, his prior 5 trades show only 1 measurable outcome (the 2024-12-02 sell), which was poorly timed (+39.7% 90-day return). The company faces significant headwinds: net income of $-53,530,000.00 against revenue of $49,301,000.00 in the latest quarter, with the company unprofitable over its most recent full fiscal year. The 30-day price momentum (+41.2%) contrasts sharply with the cross-ticker track record's average 30-day return after his sells (-14.3%), and the recent concentration of his SWTX sales (four trades in February 2025 alone) alongside this substantial March sale warrants observation of whether this pattern reflects a systematic reduction in CEO exposure.

CEO Islam Saqib sold 29.3K SWTX shares for $1.8M (blended avg $60.30) on 2025-02-20, reducing holdings 2.8%

Islam Saqib, CEO of SpringWorks Therapeutics, executed 2 separate sales totaling 29,328 shares for $1,768,400.79 on 2025-02-20. The blended average price of $60.30 compares to the current market price of $56.56, meaning the shares have declined 5.6% from the 52-week high of $59.93. At the same-ticker level, Saqib's 5 prior trades show poor timing: only 1 of these prior sales has a 90-day outcome measurable, which was positive—indicating the stock rose after he sold (poorly-timed). His cross-ticker track record shows an average 90-day return of +2.0% following 11 prior sells, with just 28.57% of those characterized as well-timed. The company generated $49.3M revenue in the latest quarter but reported a net loss of $-53.5M, highlighting material unprofitability despite 3417.3% annual revenue growth and a $4.2B market capitalization. The recent sales follow earlier sells on 2025-02-14 and 2025-02-10, showing a cluster of dispositions within days.

CEO Islam Saqib sold 10,672 shares of SWTX at $59.92 on 2025-02-14 ($639.5K); stock now $55.73.

CEO Islam Saqib sold 10,672 shares at $59.92, reducing holdings from 1,074,625 to 1,063,953 shares—a -1.0% portfolio reduction. The sale occurred near the 52-week peak ($59.28), with the stock subsequently declining 6.0% to the current $55.73. Across his prior 5 trades at SWTX, Saqib's sells have not demonstrated reliable timing: 0 of 2 measurable 90-day outcomes showed positive returns (well-timed), with 90-day returns of +1.9% and +4.4% on earlier September sales—indicating the stock typically recovered post-sale. Against that pattern, this February sale at the intra-quarter peak warrants investor attention, particularly given the company's unprofitability ($-53.5M net income in the latest full fiscal year) and the recent 30-day surge (+60.9%) that preceded the sale.

CEO Islam Saqib sold 48,000 shares at $53.30 on 2025-02-10; stock now at $59.28, up 60.2% in 30 days post-trade.

Islam Saqib, as CEO, sold 48,000 shares (4.6% of pre-transaction holdings) at $53.30, reducing his stake from 1,050,502 to 1,002,502 shares. The stock has since appreciated $59.28, representing a +60.2% gain in the 30 days following the sale. This contrasts sharply with his prior same-ticker history at SWTX: across 5 recent sales (all in 2024), 4 generated negative 30-day returns ranging from -12.6% to -24.4%, with only 1 of 3 measurable 90-day outcomes being well-timed (negative return). In this case, the sale occurred near the 52-week high of $59.28, yet the stock rallied significantly afterward—marking a poorly-timed exit relative to near-term price action. Against the backdrop of ongoing unprofitability (net income of $-53,530,000.00 in the latest quarter), the CEO's sale patterns merit close observation for whether they signal operational or strategic shifts rather than mere portfolio activity.

SWTX CEO Islam Saqib sells 49,000 shares for $2,027,357.32 in 2 transactions on 2024-12-02

Islam Saqib, CEO of SpringWorks Therapeutics, executed 2 separate sales totaling 49,000 shares for $2,027,357.32 on 2024-12-02, reducing his post-transaction holdings to 1,014,368 shares (-4.6% vs pre-transaction holdings). The blended average transaction price of $41.37 sits below the current price of $42.31, with the stock up 36.8% over the past 30 days and 5.5% over 90 days, placing it 19.4% below its 52-week high of $52.50. At the same ticker, Saqib's prior 5 trades showed mixed 90-day outcomes (2 of 5 well-timed), with the most recent September 2024 sells posting -20.6% to -24.4% 30-day returns. The company is unprofitable (latest quarter net income -$53,530,000.00 on revenue of $49,301,000.00) with a market cap of $3.1B. This represents a material CEO stake reduction in a loss-making biotech company during a recent rally phase, warranting evaluation against public disclosures regarding SpringWorks' pipeline progress and cash position.

CEO Islam Saqib sold 49,000 shares (49.0K shares) for $1,988,033.06 ($2.0M) at blended average price $40.57 on 2024-09-03.

Islam Saqib, Chief Executive Officer of SpringWorks Therapeutics, executed 3 separate sales totaling 49,000 shares for $1,988,033.06 on 2024-09-03, reducing his holdings from 1,112,368 to 1,063,368 shares (a -4.4% reduction). The company is unprofitable with net income of $-39,919,000.00 (latest quarter) and a negative full-year result. Saqib's cross-ticker track record shows 4 prior open-market sells with an average 90-day return of +2.1% and a 25.00% well-timed rate; at SWTX specifically, 1 of 4 prior sells demonstrated a negative 90-day return (well-timed). The current stock price of $40.98 reflects a +22.7% 30-day gain and sits -21.9% below the 52-week high, creating a volatile backdrop for this sale.